Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$24.92M+283.67%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul Badawi
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 186
- Beta
- 2.43
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.01
Financials
Revenue
$24.92M+283.7%Net Income
$-6.81MEBITDA
$-5.49MFree Cash Flow
$-2.47MEPS (diluted)
$-0.12Shares Outstanding (diluted)
55.13M+57.3%Operating Expenses
$27.55MCash & Debt
$77.40MRevenue by Segment (annual)
$77.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $77.36M | $-38.43M | $-0.74 |
| 2024 | $79.87M | $-51.51M | $-1.03 |
| 2023 | $81.06M | $-55.55M | $-1.14 |
| 2022 | $71.33M | $-86.24M | $-1.80 |
| 2021 | $48.96M | $-62.96M | $-1.33 |
| 2020 | $27.64M | $-34.69M | $-0.74 |
| 2019 | $23.35M | $-25.87M | $-0.55 |
| 2018 | $7.53M | $-14.29M | $-0.44 |
Valuation
SGHThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (8)
- Newsmarketbeat.com·17d ago·Neutral
What Sight Sciences (SGHT) Said on Its Q3 Earnings Call Sight Sciences NASDAQ: SGHT raised its full-year revenue outlook after reporting record third-quarter sales, driven by growth in its glaucoma business and increased adoption of its TearCare dry eye treatment.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Neutral
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2026, after the market close on Wedn…
View source ↗ - Newsseekingalpha.com·44d ago·Neutral
…y,' as recent reimbursement wins and product momentum support a positive outlook, offset by liquidity pressures and ongoing reimbursement and utilization challenges. SGHT's OMNI Ultra Surgical System launch and updated TearCare label provide incremental adoption tailwinds, but procedure costs/reimbursement and surgeon preference remain key hurdles. Q2 revenue grew 20% with strong dry eye business acceleration, improved gross margins, and reduced cash burn; Aetna coverage adds 25 million insured …
View source ↗ - Newsglobenewswire.com·52d ago·Negative
… Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the commercial availability of the OMNI® Ultra Surgical System (OMNI Ultra), an expansion of its pioneering ab intern…
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·95d ago·Negative
… to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to stat…
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.10 per share
Typical surprise +8.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.12 vs $-0.12beat
- Wed, Aug 5$-0.08 vs $-0.18beat
- Wed, May 6$-0.24 vs $-0.19miss
- Wed, Mar 4$-0.08 vs $-0.15beat
- Thu, Nov 6$-0.16 vs $-0.26beat
- Thu, Aug 7$-0.23 vs $-0.25beat
Estimates and results for SGHT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SGHT officers and directors.
- Bought
- $1.2m
- Sold
- $3.3m
9 trades
48 trades
- Taylor Brentonsold
- Bauerlein Alisonsold
- Rodberg Jamessold
- Badawi Davidsold
- Badawi Paulsold
- Hayden Jeremy B.sold
- Badawi Davidsold
- Rodberg Jamessold
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SGHT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
